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To identify factors that might predict response to sunitinib in
patients with renal cell carcinoma, we measured serum
vascular endothelial growth factor (VEGF) and neutrophil
gelatinase-associated lipocalin (NGAL) levels. A total of
85 patients were selected and, using the Motzer
classification, 46 were assigned to the good- and 38 to the
intermediate-risk groups. With univariate Cox analysis, both
baseline serum VEGF and NGAL titers, determined by
enzyme-linked immunosorbent assay, significantly predicted
progression-free survival. For each biomarker, a threshold
value was identified, which proved useful to classify patients
into groups having titers above or below the thresholds. We
then stratified patients according to the two dichotomous
variables into good-, intermediate-, and poor-risk groups,
and found significantly different progression-free survival
rates ranging from 3.5 to 11.6 months. Both VEGF and NGAL
maintained their predictive significance at bivariate analysis.
Our study shows that serum levels of VEGF and NGAL are
significant predictors of progression-free survival in patients
with renal cell carcinoma treated with sunitinib.
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Despite the recent therapeutic improvements obtained with
the use of molecularly targeted agents,1 metastatic renal cell
carcinoma (RCC) should still be considered incurable.
This lack of curative treatment options, together with the
peculiar natural history of metastatic RCC and the highly
perceived problem of the costs of the newer agents, highlight
the need for identifying both prognostic and predictive
factors in these patients.2
Despite decades of clinical research,3 Motzer (or MSKCC)
criteria remain the most reliable prognostic factors available
for advanced RCC patients.
Motzer et al.4 studied 670 advanced RCC patients treated
with immunotherapy or chemotherapy and identified, using
multivariate analysis, five pre-treatment features that were
significantly associated with shorter survival, namely, low
Karnofsky performance status, high lactate dehydrogenase
levels, low hemoglobin levels, high corrected calcium levels,
and no nephrectomy. Using these factors, they stratified
patients into three groups (good-, intermediate-, and poor-
risk groups) that had a completely different prognosis, that is,
from 20 months for the good prognosis group to just 4
months for the poor prognosis group.4
A similar analysis was then applied to 400 patients treated
with interferon-a as first-line systemic therapy; this analysis
reduced the heterogeneity caused by multiple treatments and
highlighted the essential role of cytoreductive nephrectomy
in metastatic patients with a good performance status. Still,
the prognostic model remained the same, except that time
from diagnosis to treatment with interferon-a o1, year was
replaced with absence of previous nephrectomy.5
More recently, the same group reviewed clinical and
laboratory data relative to 137 patients enrolled into clinical
trials with more modern treatments (from 1990 onward6)
and evidenced the following independent predictors of worse
survival, namely, poor Karnofsky performance status, low
hemoglobin, and elevated corrected serum calcium. Again,
the number of poor prognostic variables stratified patients
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into favorable- (no risk factors), intermediate- (one risk
factor), and poor-risk (two or three risk factors) groups,
which had overall 1- and 3-year survival rates of 76 and 25%,
49 and 11%, and 11 and 0%, respectively.
Despite the fact that the above prognostic models and
predictors of outcome were identified in patients who mainly
received immunotherapy, hormonal therapy, and/or che-
motherapy, the applicability of the MSKCC criteria in the era
of molecularly targeted agents has been confirmed by
subgroup analysis of both registrative trials and large
expanded access programmes.
With the advent of molecularly targeted therapies,
molecular tumor markers have the potential to considerably
improve attempts to individualize patient prognosis and
treatment strategies.1
We investigated the potential predictive factors of
sunitinib malate antitumor activity through the assessment
of serum levels of soluble vascular endothelial growth factor
(VEGF) and of neutrophil gelatinase-associated lipocalin
(NGAL).
Vascular endothelial growth factor, the most important
pro-angiogenic cytokine, is particularly relevant in kidney
cancer owing to the peculiar pathogenesis of this neoplasm
(that is, the deletion/mutation of the Von Hippel-Lindau
(VHL) protein, leading to an overproduction of pro-
angiogenic cytokines through hypoxia-inducible factor-1
(HIF-1) stabilization),7 whereas NGAL is a protein typically
upregulated in cells under ‘stress’, for example, in the
presence of a tumor,8 and is tightly correlated with matrix
metalloproteinase-9 (MMP-9),9 another key protein involved
in the degradation of the extracellular matrix, and thus in
invasion and metastasis. Furthermore, NGAL can protect the
kidney against acute ischemic injury,10 has a role in self-
survival, and has been observed to be elevated in a number of
human cancers, in which its role seems to be different
depending on different tumor types.11
RESULTS
Patients’ characteristics and sunitinib efficacy in terms of
progression-free survival
In total, 85 patients received sunitinib; the average age of our
patient population was 59.77 years (median: 60; range: 35–77
years); 60 patients had a pure clear-cell RCC, whereas 12 had
a predominantly clear-cell mixed histotype and 13 a pure
non-clear-cell histotype. The Motzer score4 only detected
favorable (n¼ 46) and intermediate (n¼ 38) prognosis
patients, with no poor-risk patients. The Motzer score was
evaluated in all but one patient because some requested
biochemical tests were missing on enrollment.
Patients’ characteristics are reported in Table 1.
At the time of analysis, average progression-free survival
(PFS) was 10.4 months (median: 7.5, interquartile (IQ)
range: 2.9–15.4; range: 0.76–30.02 months).
As far as compliance to sunitinib treatment, a dose reduction
to either 37.5 or 25mg, due to toxicity, was carried out in
35 patients (41%). Unexpected toxicities were not recorded.
Baseline serum VEGF and NGAL titers
Of the 85 patients assessed, 52 (61%) had serum VEGF values
within the normal range (0–707 pg/ml), with a median
baseline value of 560.24 (IQ range: 347.25–958.18; range:
44.16–4522.41).
Neutrophil gelatinase-associated lipocalin baseline value
was within the normal range (42–177 ng/ml) in 56
patients (66%). Low and high values were detected in 12
and 17 patients, respectively. The median baseline value was
83.2 ng/ml (IQ range: 62.2–140.4; range: 2.8–363.4).
The VEGF and NGAL normal ranges used for the purpose
of this study were those indicated by the manufacturers of the
commercial kits we used.
No correlation was found between either glomerular
filtration rate or creatinine and NGAL values (data not
shown).
Univariate analysis of the predictive role of Motzer score,
VEGF, and NGAL basal titers
All predictive relationships were investigated in 84 (of 85)
patients, in which all the three variables investigated (that is,
Motzer score, VEGF and NGAL basal titers) were available.
Using the univariate Cox analysis (Table 2), in our case
series the Motzer score was not predictive of PFS. Figure 1
shows the PFS curves for favorable and intermediate Motzer
scores: the score is predictive of the outcome only in the short
term (up to about 1 year), whereas in a longer term, the two
curves overlap.
As for VEGF and NGAL, their baseline values were
significant predictors of PFS; as shown in Table 2, the
relative risk (RR) for a unitary increase of these parameters is
Table 1 | Patients’ characteristics
Patients’ characteristics (n=85)
Median age, years (range) 60 (35–77)
Male/female 72/13
ECOG performance status
0 67
1–2 18
Histology
Clear cell 60
Mixed 12
Others 13
Motzer’s score
Good 46
Intermediate 38
Poor 0
Not available 1
Previous therapy lines (n)
0 1
1–3 74
43 10
Median number of metastatic sites (range) 3.2 (1–7)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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1.0004 and 1.004, respectively, meaning that if we consider
two generic patients, P1 with a VGEF value equal to v1, and P2
with VGEF value equal to v1þ 100, the RR of P2 with respect
to P1 is 4%. The same holds true for two patients, in whom
P1 has an NGAL value equal to n1 and P2 an NGAL value
equal to n1þ 10.
To better interpret the predictive value of VEGF and
NGAL, that is, the RR values found by the Cox regression
model, threshold values were identified that better correlated
with PFS. Thus, patients were subdivided into two groups
according to whether their VEGF and NGAL values were
above or below the threshold.
As for VEGF, the histogram shown in Figure 2a does not
show a clear bimodal distribution; however, we chose a
threshold value corresponding to the upper value of the
normal range (707 pg/ml); patients with a baseline VEGF
titer above this threshold had a RR of progressing of 2.14
(95%CI: 1.324–3.459), relative to patients with a value below
the threshold. Thus, this threshold value allowed us to
discriminate two patient groups with significantly different
PFS, as shown in Figure 2b. Different from Figure 1, in which
the Motzer score was considered, groups distinguished by
this VEGF threshold maintain a different prognosis up to the
longest follow-up.
As for NGAL, the histogram reported in Figure 3a shows a
bimodal distribution, with the separation line close to the
upper value of the normal range (177 ng/ml). Patients with a
baseline titer above this threshold had a RR of progressing of
1.86 (95% CI: 1.142–3.019), relative to patients with values
below the threshold.
Considering this threshold, the resulting PFS survival curves
are those reported in Figure 3b. Even if less separated than those
of VEGF, the two curves maintain their difference in time.
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Figure 1 | Survival curves of patients with favorable (¼ 0) or
intermediate (¼ 1) Motzer score. Although different up to
about 1 year, the two groups come to a similar prognosis, the
resulting overall difference being not significant.
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Figure 2 |VEGF value distribution and relationship to PFS.
(a) Histogram showing vascular endothelial growth factor (VEGF)
value distribution. (b) Survival curves of patients with VEGF values
below and above the threshold.
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Figure 3 |NGAL value distribution and relationship to PFS.
(a) Histogram showing neutrophil gelatinase-associated lipocalin
(NGAL) value distribution. (b) Survival curves of patients with
NGAL values below and above the threshold.
Table 2 | Univariate Cox proportional hazard model for PFS
analysis
Parameter Coefficient Relative risk (95% CI) P-value
Motzer’s score 0.168 1.18 (0.73–1.90) 0.49
VEGF 0.0004 1.0004 (1.00037–1.00042) 0.004
NGAL 0.004 1.004 (1.00045–1.00734) 0.02
Abbreviations: CI, confidence interval; NGAL, neutrophil gelatinase-associated
lipocalin; PFS, progression-free survival; VEGF, vascular endothelial growth factor.
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For purely descriptive purposes (the statistical inference
was done by means of survival analysis), Table 3 shows the
absolute number of progressing and non-progressing patients
according to dichotomized variables, that is, Motzer favor-
able and intermediate groups and normal or above-threshold
VEGF and NGAL titers.
The probability of being progression free at 3 months,
6 months, 1 year, 18 months and 2 years according to the
baseline VEGF and NGAL titers are reported in Table 4.
Furthermore, patients with above-threshold VEGF titers
have a median PFS of 4.7 months (95% CI: 2.8–8.3), whereas
patients with VEGF titers below the threshold have a median
PFS of 11.2 months (95% CI: 6.5–15). Patients with above-
threshold NGAL titers have a median PFS of 3.35 months
(95% CI: 2.3–10.9), whereas patients with NGAL titers below
the threshold have a median PFS of 8.15 months (95% CI:
5.5–11.6).
Bivariate analysis
The predictive value of the two considered parameters (that
is, VEGF and NGAL), already evidenced as statistically
significant at univariate analysis, was then studied in bivariate
analysis; both VEGF and NGAL maintained their signifi-
cance, once NGAL threshold for high values was set to 110
instead of 177 (P¼ 0.0048 and P¼ 0.034, respectively). RRs
for VEGF and NGAL and their 95% CI were 2.04
(1.236–3.267) and 1.65 (1.041–2.775), respectively.
We then grouped patients according to VEGF and NGAL
values into three groups, namely, patients with both titers
below the threshold, patients with both titers over the
threshold, and patients with either titer above the threshold
and the other one below. The resulting PFS curves for the
three groups are reported in Figure 4.
Multivariate analysis
As a possible confounding role of other known prognostic
factors could be postulated, a multivariate analysis that also
included age and histology (clear-cell or non-clear-cell) was
performed; previous treatments were not included in this
analysis, as only one patient from this series was treatment
naive. Once again, both VEGF and NGAL remained
significant, whereas age and histology were not; indeed, the
RR for VEGF and NGAL were 1.96 (95% CI: 1.47–2.45) and
1.91 (95% CI: 1.39–2.42), respectively.
DISCUSSION
Until recently, therapeutic options for patients with advanced
RCC were limited, but things have changed dramatically over
the past few years. Improved understanding of the biology of
RCC has permitted the development of novel targeted
therapeutic agents that have altered the natural history of
this disease.12 In particular, sunitinib has become one of the
two reference first-line treatments available in RCC and likely
the most commonly and widely used drug in this setting.13
Nevertheless, all the treatments developed so far do not
benefit every single patient and the disease itself remains
uncurable. Identifying both prognostic and predictive factors
in these patients has thus become a priority.
Table 3 | Counting tables correlating progression of disease with basal values under/over the threshold
VEGFp
707pg/ml
VEGF4
707pg/ml
NGALp
177ng/ml
NGAL4
177ng/ml
Motzer
score=good
Motzer
score=intermediate
Not progressed 13 1 11 3 8 6
Progressed 39 32 44 27 38 32
Abbreviations: NGAL, neutrophil gelatinase-associated lipocalin; VEGF, vascular endothelial growth factor.
Table 4 | Number of patients at risk and percent PFS at 3, 6, 12, 18, and 24 months
3 months,
percentage (n)
6 months,
percentage (n)
1 year,
percentage (n)
18 months,
percentage (n)
2 years,
percentage (n)
VEGFo707 pg/ml 80 (42) 65 (35) 43 (23) 31 (17) 24 (10)
VEGFX707 pg/ml 61 (21) 42 (15) 15 (6) 6 (3) 6 (3)
NGALo177 ng/ml 78 (53) 60 (43) 35 (25) 23 (17) 17 (13)
NGALX177 ng/ml 50 (10) 34 (7) 17 (4) 11 (3) 5 (1)
Abbreviations: NGAL, neutrophil gelatinase-associated lipocalin; VEGF, vascular endothelial growth factor.
P = 0.006
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Figure 4 | Survival curves of patients with both vascular
endothelial growth factor (VEGF) and neutrophil gelatinase-
associated lipocalin (NGAL) titers below the threshold, with
both VEGF and NGAL titers above the threshold, and with
either value above the threshold and the other one below.
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An impressive number of prognostic and predictive factors
have been proposed in Medical Oncology for virtually all
tumor histotypes, but they usually failed to prove to be more
reliable than the best clinical predictive/prognostic factors
available and thus they often lacked any practical relevance.
As for RCC, despite all the efforts these factors are still
clinical, namely, the so-called Motzer criteria.
We have found that, in an unselected population of
advanced RCC patients treated with sunitinib malate, two
circulating cytokines, VEGF and NGAL, are more reliable
predictors of PFS than the classical Motzer criteria.
Our RCC patients with a baseline VEGF titer above a
given threshold had a RR of progressing more than twofold
higher than the patients with a value below the threshold,
and VEGF maintained its predictive value up to the longest
follow-up.
As for NGAL, patients with a baseline titer above the
threshold had a RR of progressing of 1.86 relative to patients
with a value below the threshold.
The predictive value of the VEGF and NGAL still remained
significant also when analyzed with bivariate analysis.
On the contrary, Motzer criteria proved to be reliable
predictors of outcome only in the short term (up to about
1 year), whereas in a longer term the two PFS curves overlap.
As for VEGF, its predictive importance in RCC is quite
obvious. RCC is often characterized, from a molecular
viewpoint, by the loss of the VHL tumor suppressor gene,
which results in the dysregulation of one of the key
mechanisms responsible for cellular response to hypoxia.14
Indeed, the VHL protein is involved in the degradation of the
a-subunit of HIF-1, a heterodimeric transcription factor
that regulates a program of gene expression engaged in
facilitating adaptation to tissue hypoxia. Unlike normal cells,
cells deficient in VHL inappropriately accumulate HIF-a
under conditions of normoxia, and overexpress HIF-
regulated genes, ultimately resulting in the overproduction
of several pro-angiogenic factors, the most important of
which is VEGF.14,15
As for NGAL, its involvement in RCC pathogenesis is
more subtle.
Neutrophil gelatinase-associated lipocalin belongs to the
lipocalin family of proteins, typically small secreted proteins
characterized by their ability to bind small, hydrophobic
molecules in a structurally conserved pocket formed by
b-pleated sheet, to bind to specific cell-surface receptors, and
to form macromolecular complexes. In neutrophils (neutro-
philic polymorphonuclear leukocytes) and urine, it occurs as
a monomer, with a small percentage of dimers and trimers,
and also in complex with 92-kDa human neutrophil type IV
collagenase, also called gelatinase B or MMP-9.9 NGAL was
originally isolated from the supernatant of activated human
neutrophils,8 but it is also expressed at a low level in other
human tissues including the kidney, prostate, and epithelia of
the respiratory and alimentary tracts;16 it is strongly
expressed in inflammatory, pre-tumoral and neoplastic
lesions.11,17–20
Although its functions are not fully understood, NGAL
seems to be upregulated in cells under ‘stress’, for example,
from infection, inflammation, ischemia or neoplastic trans-
formation, or in tissues undergoing involution. Its complex
formation with MMP-9 seems to protect MMP-9 enzymatic
activity from degradation.9 The upregulation of NGAL in
involuting tissues suggests that it may have a role in
apoptosis, but in fact NGAL seems more likely to be
associated with a survival response.11 This seems to be the
case in the kidney, in which NGAL siderophore–iron
complexes protect the mouse kidney from ischemic injury.10
In particular, the above tight relationship of NGAL with
MMP-9 suggests a role for NGAL in angiogenesis also;
indeed, much experimental evidence supports the direct
involvement of MMP-9 (which we did not considered in this
study) in angiogenesis.21,22
As VEGF and NGAL significantly correlated one with the
other, as NGAL could also be considered a marker of kidney
injury, and as the vast majority of our patients were
nephrectomized, we also checked whether there was any
relationship between NGAL and both serum creatinine levels
and glomerular filtration rate, but no significant correlation
between the two parameters was evidenced in our case series.
Theoretically, the observed increase in VEGF and NGAL
may derive from sites other than the kidney, hence, diluting
the impact of our findings; however, both VEGF and NGAL
expression by neoplastic or stressed kidneys have been well
documented in the literature.
In conclusion, our study showed that both circulating
VEGF and NGAL titers are predictive of a longer PFS in
kidney cancer patients treated with sunitinib malate and that
both factors performed better than the best clinical factors
available so far, that is, the Motzer score.
These parameters, which are easy to evaluate and are
reproducible in routine clinical practice also, could thus be
included in newer scoring systems/prognostic or predictive
nomograms to be routinely applied in clinical practice.
MATERIALS AND METHODS
Patients
A total of 85 patients with advanced RCC were studied. Patients had
mainly (but not exclusively) clear-cell histology, age X18 years, an
ECOG (Eastern Cooperative Oncology Group) performance status
p2, measurable metastatic disease, and adequate hematological,
hepatic, renal, and cardiac functions. They had also been treated
with non-molecularly targeted agents.
All patients voluntarily consented to participate in both the
clinical and the biological study.
Treatment schedule and disease assessment
Patients were treated with sunitinib malate at the starting dose of
50mg/day, with the classical 4 weeks on/2 weeks off schedule, within
the global expanded access program (EAP, NCT00130897).23
Sunitinib was self-administered orally once daily irrespective of
meals. Dose reduction for toxicity to 37.5mg/day and then to
25mg/day was allowed depending on the severity of the side effects
reported. The above treatment was approved by the institutional
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review board of our Hospital and performed in accordance with the
Declaration of Helsinki and good clinical practice guidelines.
Tumor assessment was performed at every two cycles (that is, 12
weeks) according to the Response Evaluation Criteria in Solid
Tumors (RECIST).24
Treatment end point
For the purpose of this paper, the primary end point was PFS,
defined as the time from enrollment to the first observation of
disease progression or death. Usually, PFS is an important surrogate
of overall survival but, as it could reflect patient benefit by
prolonging the interval to disease progression, it may also be
important as an end point in itself.25
At the time of this analysis (the data lock for this study was 30th
March 2008), the median observation period for the whole patient
population was 25.82 months, with 13 patients still under active
treatment.
Collection of biological samples
Blood samples for VEGF and NGAL were drawn early in the
morning after overnight fasting, immediately before treatment start.
A blood aliquot was then collected into a whole blood (non heparin)
tube and allowed to separate at room temperature for 30min before
being centrifuged at 1000 g for 15min. The serum thus obtained was
immediately frozen at 801C for subsequent assaying.
Serum human VEGF and lipocalin-2/NGAL assays
The two assays use the quantitative sandwich enzyme immunoassay
(enzyme-linked immunosorbent assay; ELISA) technique (R&D
Systems, Milan, Italy). Briefly, a monoclonal antibody specific for
VEGF or NGAL is pre-coated into a microplate; standards and
samples are then pipetted into the wells and any VEGF present is
therefore bound by the immobilized antibody. After washing away
any unbound substances, an enzyme-liked polyclonal antibody
specific for VEGF or NGAL is added to the wells. Following another
wash to remove any unbound antibody–enzyme reagent, a substrate
solution is added to the well and color develops proportionally to
the amount of VEGF or NGAL bound in the initial step. Color
development is stopped and color intensity is measured. Sensitivity
is expressed as pg/ml for VEGF and ng/ml for NGAL. The minimum
detectable dose (MDD) was determined by adding two standard
deviations to the mean optical density value of twenty zero standard
and calculating the corresponding concentration.
Sensitivity is expressed as pg/ml for VEGF and ng/ml for NGAL.
The MDD of VEGF is typicallyo5.0 pg/ml and the mean MDD for
NGAL is 0.012 ng/ml. Inter and intra-assay coefficients of variation
are 7.3 and 5.4%, respectively, for VEGF, and 6.5 and 3.7%,
respectively, for NGAL. The range of values is 62–707 pg/ml for
VEGF and 42–177 ng/ml for NGAL.
As NGAL could also be considered a marker of kidney injury, we
also checked a possible correlation between NGAL and both serum
creatinine as well as GFR.
Data analysis and statistics
Vascular endothelial growth factor and NGAL serum concentrations
were analyzed and correlated with PFS and the original Motzer score.4
Descriptive statistics are reported as median, IQ range, and
whole range. We preferred non-parametric statistics because of the
non-normal distribution of variables. Logarithmic transformation
was applied to improve normality of VEGF distribution. Histograms
of variable distributions were used to detect possible thresholds,
suitable for classifying patients in low/high variable value groups;
both continuous and dichotomized values were tested in statistical
models. Survival curves were drawn according to Kaplan–Meier
estimate and log-rank test was used to test the difference between
two or more survival curves. Cox’s proportional hazards model,
both uni- and multivariate, was used to test the statistical
significance of potential PFS predictors. RR associated to a
prognostic factor was computed as the antilogarithm of the
corresponding coefficient in the Cox regression model.
Boxplots were drawn to visualize a variable difference between
two groups. They show the median, IQ (25th and 75th percentile),
and whiskers extending to the most extreme data point, which is no
more than 1.5 times the IQ range from the box. Individual outliers
are also shown beyond whiskers. Correlation between two
continuous variables was tested through the Pearson or Spearman
coefficient.
The statistical package S-PLUS (TIBCO Software, Palo Alto, CA,
USA) was used for all the statistics.26
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